Purdue Pharma successfully resolves Hatch-Waxman claims against companies seeking to make generic version of transdermal patch Butrans®
Client(s) Purdue Pharma L.P.
Jones Day client Purdue Pharma L.P. successfully resolved a patent infringement action it brought under the Hatch-Waxman Act against two companies that sought FDA approval to market a generic version of Purdue's Butrans® product prior to the expiration of certain patents owned by Purdue. Butrans® is a transdermal patch that delivers buprenorphine, a potent medication used for the treatment of chronic pain.
Purdue Pharma L.P. v. Watson Laboratories, Inc., C.A. No. 14-1227 (D. Del.) (SLR) (SRF)